Mounjaro Gets Green Light from Expert Committee for Weight Management

Eli Lilly must fulfill the Subject Expert Committee requirements, including submitting data related to manufacturing and quality control processes

91
Expert Committee Meeting
Picture: Pixabay

Last Updated on July 12, 2024 by The Health Master

Expert Committee

The Indian healthcare landscape is poised for a significant change as subject expert committee (SEC) has recommended the import and sale of Mounjaro, a revolutionary drug from Eli Lilly.

his news, revealed on a government website on June 19th, holds immense potential for millions struggling with weight management and type 2 diabetes in India.

Mounjaro: A Multi-Faceted Weapon Against Weight and Diabetes

Mounjaro, also known by its chemical name tirzepatide, belongs to a new class of drugs called GLP-1 receptor agonists.

Primarily developed to control blood sugar levels in type 2 diabetes patients, Mounjaro offers an additional benefit – it slows down digestion, promoting a feeling of fullness and aiding weight loss.

This unique dual action has made Mounjaro a highly sought-after treatment option globally.

Subject Expert Committee Recommends Approval with Conditions

The Subject Expert Committee (SEC), which advises India’s drug regulator on drug approvals, has recommended granting permission for Mounjaro’s import and sale specifically for chronic weight management.

Their recommendation, however, comes with a crucial stipulation: Eli Lilly must conduct Phase 4 clinical trials, also known as post-marketing surveillance, after the drug’s launch.

This additional research phase helps monitor the drug’s long-term effects and safety in the Indian population.

India: A Prime Market for Weight-Loss Solutions

This development holds particular significance for India, which grapples with the world’s second-highest number of type 2 diabetes patients.

Furthermore, obesity rates in India are projected to rise dramatically, with projections suggesting that nearly 11% of Indian adults will be obese by 2035, according to the World Obesity Federation Atlas.

Considering this alarming trend, Mounjaro’s potential to address both weight and diabetes concerns makes it a highly anticipated addition to the Indian healthcare market.

Global Market Boom for Weight-Loss Drugs

The global weight-loss drug market is expected to experience a phenomenal surge, with estimations suggesting it could reach a staggering $100 billion by the end of this decade.

Mounjaro’s potential approval in India positions Eli Lilly to tap into this burgeoning market, offering a much-needed solution for millions struggling with weight management and its associated health risks.

Looking Ahead

While the Subject Expert Committee (SEC) recommendation is a significant step forward, it’s not the final hurdle.

Eli Lilly must fulfill the Subject Expert Committee (SEC) requirements, including submitting data related to manufacturing and quality control processes.

Once these requirements are met, and final approval is granted, Mounjaro could be available in India as early as next year, as per previous statements by Eli Lilly CEO David Ricks.

This development signifies a potential turning point in India’s fight against obesity and type 2 diabetes.

With Mounjaro’s potential arrival, millions of individuals could have a powerful tool to manage their weight and improve their overall health.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news